Tina Etminan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tina Etminan has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Abbey Rocco
Division of Pediatric Hematology and Oncology, Department of Pediatrics, The University of Alabama at Birmingham, Birmingham, Alabama. 1
27 shared publications - Elizabeth A. Beierle
Division of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA
27 shared publications - G. Yancey Gillespie
10Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, Alabama
27 shared publications - Gregory K. Friedman
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, USA
27 shared publications - James M. Markert
Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA
27 shared publications - Joshua D. Bernstock
Department of Neurosurgery, Brigham and Women’s Hospital, Mass General Brigham, Boston, Massachusetts
27 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Toxicity from IVT oHSV in the left lateral ventricle and third and fourth ventricles at different time points.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Toxicity from IVT oHSV in the left lateral ventricle and third and fourth ventricles at different time points.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Interferon β (IFN β) levels over time in the CSF after a single 50 µg IVT dose of poly I:C or saline (N = 2 mice/group/time point).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Interferon β (IFN β) levels over time in the CSF after a single 50 µg IVT dose of poly I:C or saline (N = 2 mice/group/time point).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Toxicity with repeated doses of IVT oHSV.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Toxicity with repeated doses of IVT oHSV.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Body weights of CBA/J, BALB/c and C57BL/6 mice (N = 5/group) after inoculation with 1x107 PFU of IVT oHSV.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Body weights of CBA/J, BALB/c and C57BL/6 mice (N = 5/group) after inoculation with 1x107 PFU of IVT oHSV.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Comparison of the protective effect of different pretreatment low doses of IVT oHSV from toxicity after a subsequent treatment dose.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Comparison of the protective effect of different pretreatment low doses of IVT oHSV from toxicity after a subsequent treatment dose.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Time to recover baseline body weight in mice pretreated with low-dose oHSV prior to a standard treatment dose.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Time to recover baseline body weight in mice pretreated with low-dose oHSV prior to a standard treatment dose.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
IHC staining of the ependymal lining for CD8+ cells and confirmation of CD8 depletion.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
IHC staining of the ependymal lining for CD8+ cells and confirmation of CD8 depletion.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Effects of poly I:C alone and combined with oHSV in vitro and in vivo.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Effects of poly I:C alone and combined with oHSV in vitro and in vivo.
- Open Access
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S8 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Effects of poly I:C alone and combined with oHSV in vitro and in vivo.
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Effects of poly I:C alone and combined with oHSV in vitro and in vivo.
- Open Access
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Purpose:Oncolytic virotherapy with herpes simplex virus-1 (HSV) has shown promise for the treatment of pediatric and adult brain tumors; however, completed and ongoing clinical trials have utilized intratumoral/peritumoral oncolytic HSV (oHSV) inoculation due to intraventricular/intrathecal toxicity concerns. Intratumoral delivery requires an invasive neurosurgical procedure, limits repeat injections, and precludes direct targeting of metastatic and leptomeningeal disease. To address these limitations, we determined causes of toxicity from intraventricular oHSV and established methods for mitigating toxicity to treat disseminated brain tumors in mice.Experimental Design:HSV-sensitive CBA/J mice received intraventricular vehicle, inactivated oHSV, or treatment doses (1×107 plaque-forming units) of oHSV, and toxicity was assessed by weight loss and IHC. Protective strategies to reduce oHSV toxicity, including intraventricular low-dose oHSV or interferon inducer polyinosinic-polycytidylic acid (poly I:C) prior to oHSV treatment dose, were evaluated and then utilized to assess intraventricular oHSV treatment of multiple models of disseminated CNS disease.Results:A standard treatment dose of intraventricular oHSV damaged ependymal cells via virus replication and induction of CD8+ T cells, whereas vehicle or inactivated virus resulted in no toxicity. Subsequent doses of intraventricular oHSV caused little additional toxicity. Interferon induction with phosphorylation of eukaryotic initiation factor-2α (eIF2α) via intraventricular pretreatment with low-dose oHSV or poly I:C mitigated ependyma toxicity. This approach enabled the safe delivery of multiple treatment doses of clinically relevant oHSV G207 and prolonged survival in disseminated brain tumor models.Conclusions:Toxicity from intraventricular oHSV can be mitigated, resulting in therapeutic benefit. These data support the clinical translation of intraventricular G207.
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Purpose:Oncolytic virotherapy with herpes simplex virus-1 (HSV) has shown promise for the treatment of pediatric and adult brain tumors; however, completed and ongoing clinical trials have utilized intratumoral/peritumoral oncolytic HSV (oHSV) inoculation due to intraventricular/intrathecal toxicity concerns. Intratumoral delivery requires an invasive neurosurgical procedure, limits repeat injections, and precludes direct targeting of metastatic and leptomeningeal disease. To address these limitations, we determined causes of toxicity from intraventricular oHSV and established methods for mitigating toxicity to treat disseminated brain tumors in mice.Experimental Design:HSV-sensitive CBA/J mice received intraventricular vehicle, inactivated oHSV, or treatment doses (1×107 plaque-forming units) of oHSV, and toxicity was assessed by weight loss and IHC. Protective strategies to reduce oHSV toxicity, including intraventricular low-dose oHSV or interferon inducer polyinosinic-polycytidylic acid (poly I:C) prior to oHSV treatment dose, were evaluated and then utilized to assess intraventricular oHSV treatment of multiple models of disseminated CNS disease.Results:A standard treatment dose of intraventricular oHSV damaged ependymal cells via virus replication and induction of CD8+ T cells, whereas vehicle or inactivated virus resulted in no toxicity. Subsequent doses of intraventricular oHSV caused little additional toxicity. Interferon induction with phosphorylation of eukaryotic initiation factor-2α (eIF2α) via intraventricular pretreatment with low-dose oHSV or poly I:C mitigated ependyma toxicity. This approach enabled the safe delivery of multiple treatment doses of clinically relevant oHSV G207 and prolonged survival in disseminated brain tumor models.Conclusions:Toxicity from intraventricular oHSV can be mitigated, resulting in therapeutic benefit. These data support the clinical translation of intraventricular G207.